DSP502 / Kahr Medical - LARVOL DELTA

DSP502 combines dual inhibition of PD-L1 and PVR to trigger anti-cancer immune responses. (PubMed, Mol Cancer Ther) - "Finally, DSP502 inhibited tumor growth by potentiating antitumor immunity in xenograft ovarian and lung cancer models. Collectively, these findings demonstrate that DSP502, by blocking PVR and PD-L1 pathways, has dual ICI activity and holds potential therapeutic benefits for cancers such as NSCLC."

IO biomarker • Journal • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD8 • PVR • TIGIT

DSP502 — A Novel Approach For Targeting TIGIT And PD1 Pathways For Cancer Immunotherapy (SITC 2021) - "Beyond targeting PVR and PDL1, DSP502 has the potential to additionally impact the TIGIT pathway through its effects on CD96 and DNAM1. DSP502 is currently in IND-enabling studies and CMC development."

IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • GZMB • PD-1 • TIGIT

KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline (PRNewswire) - “Proceeds from the financing will be used to advance clinical development of the Company's lead product candidate, DSP107, a first-in-class CD47x41BB targeting fusion protein for the treatment of solid and blood cancers, through multiple Phase 1/2 studies as well as the development of its preclinical pipeline including DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein, through IND-enabling studies.”

Commercial • Hematological Malignancies • Oncology • Solid Tumor

Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate (PRNewswire) - “Samsung Biologics…signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins. Under the terms of the agreement, Samsung Biologics will provide its end-to-end cell line development and clinical drug substance and drug product manufacturing services as well as IND filling support for KAHR's drug candidate DSP502, a TIGITxPD1 fusion protein…KAHR recently signed an exclusive license with Thomas Jefferson University in Philadelphia, PA to develop and commercialize multiple new drug candidates, including DSP502.”

IND • Licensing / partnership • Oncology

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy (PRNewswire) - “KAHR…announced today that it has entered into a licensing agreement with Thomas Jefferson University -- a national doctoral research university -- and its clinical enterprise, Jefferson Health, located in Philadelphia, PA. Under the agreement, Thomas Jefferson University is granting KAHR an exclusive license to develop and commercialize multiple new drug candidates including DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein for immuno-oncology.”

Licensing / partnership • Oncology